Exome Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Exome Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.24M	Sell	166,493 -48,883	-23%	-$886K	2%	19
2026 Q1	$4.01M	Buy	+215,376	New	+$3.57M	2.08%	16
2025 Q4	–	Sell	-178,084	Closed	-$1.28M	–	77
2025 Q3	$1.28M	Buy	+178,084	New	+$9.28M	0.77%	46
2024 Q1	–	Sell	-9,744	Closed	-$588K	–	66
2023 Q4	$588K	Buy	+9,744	New	+$502K	0.58%	46

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Exome Asset Management's MLTX Position: Q2 2026 in Review

Exome Asset Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 23% in Q2 2026, selling an estimated $886K and leaving 166,493 shares worth $3.24M. The position accounts for 2% of the portfolio, ranked #19.

Exome Asset Management first reported a position in MLTX in Q4 2023 and has held it in 4 quarters since. The position peaked at $4.01M in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Exome Asset Management held 166,493 shares of MoonLake Immunotherapeutics worth $3.24M as of Q2 2026.
Exome Asset Management sold 48,883 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $886K.
MoonLake Immunotherapeutics made up 2% of Exome Asset Management's portfolio in Q2 2026, its #19 holding.
Exome Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 4 quarters since.
Exome Asset Management's MoonLake Immunotherapeutics position peaked at $4.01M in Q1 2026.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.